Frontlight ResearchEarly access
CompletedPhase 2
A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
Key facts
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 22 people enrolled
- Started
- 22 Jan 2023
- Ended
- 30 Dec 2023
- Type of study
- Interventional
- Treatments tested
- CM313 Injection
- Record updated
- 24 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (24)Hide the full registry criteria
Who can take part
- Age 18 and above, male or female
- Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)
- Diagnosis of ITP ≥3 months, and with a platelet count of <30 X 109/L measured within 2 days prior to inclusion
- Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab or TPORAs
- The previous emergency treatment of ITP (e.g. methylprednisolone, platelet transfusion, IVIG transfusion) must be completed at least 2 weeks before the first administration
- Signed and dated written informed consent
- With normal hepatic and renal functions
- ECOG physical state score ≤ 2 points
- Cardiac function of the New York Society of Cardiac Function ≤ 2
- Patients receiving maintenance treatment (including corticosteroids (less than or equal to 0.5mg/kg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration, and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of rituximab treatment was>3 months;More than 6 months after splenectomy; April 10, 2023 After approval by the Ethics Committee on , subjects no longer require platelet glycoprotein autoantibodies positivity upon enrollment
Who cannot take part
- Received any treatment of anti-CD38 antibody drug
- Those who have received allogeneic stem cell transplantation or organ transplantation in the past
- Patients taking antiplatelet drugs at the same time
- Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases
- HIV positive
- Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive
- Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
- At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled
- Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis
- Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up
- Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.)
- Patients with septicemia or other irregular severe bleeding
- Patients whose toxic symptoms caused by pre-trial treatment have not disappeared
- Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and efficacy of CM313 in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including rituximab and/or TPO-RA.
The group in the trial
- Intervention (CM313)Treatment being tested
20 enrolled subjects: once a week x 8 doses
Treatment: CM313 Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD38 Monoclonal Antibody CM313 in the Treatment of Primary Immune Thrombocytopenia
- Publications
- A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.The New England journal of medicine, 2024
- Record updated
- 24 February 2025